How much weight comes back after stopping GLP-1 drugs?
The weight regain after stopping GLP-1 drugs is substantial and drug-dependent. A 2025 meta-analysis of 36 studies found that people who stopped semaglutide regained an average of 5.15 kg (about 11.3 pounds) after reaching their peak weight loss [1]. That's roughly half or more of the weight typically lost on these drugs, meaning many patients end up close to their starting weight. For liraglutide, the regain was smaller—about 1.5 kg (3.3 pounds)—but still significant [1]. This isn't just a cosmetic issue; it's a clinical one because the weight comes back with the same metabolic risks.
Does the rebound change how people eat?
Yes, the rebound appears to reverse the positive eating-behavior changes that GLP-1 drugs produce. While on the medication, people report feeling more in tune with hunger and fullness cues and less driven by emotional or external triggers like stress or food ads [4]. But when the drug is stopped, those benefits fade. A 2025 survey of 101 patients found that after stopping GLP-1s, the frequency of eating past fullness and eating in response to emotions, situations, and sensory cues all significantly increased [4]. This suggests that the rebound isn't just about calories—it's a return to the same disordered eating patterns that contributed to obesity in the first place.
This behavioral shift is especially concerning because it can feed into night eating and binge eating. A 2022 study of over 1,000 adults found that night eating severity was linked to higher BMI, more fast food and sugary drink intake, and less healthy eating overall [3]. Similarly, a 2023 study showed that semaglutide actually reduced binge eating symptoms in people with binge eating disorder [6]. So when the drug stops, those binge urges can come back, potentially worsening the cycle of weight regain.
Why does this matter for public health?
The public health concern is that weight rebound on a large scale could normalize or worsen unhealthy eating behaviors across the population. Weight stigma itself—which often increases when people regain weight—is linked to more disordered eating, comfort eating, and alcohol use, even after controlling for BMI [2]. So the rebound creates a double hit: the person regains weight and also experiences more stigma, which in turn drives more unhealthy eating. This could make it harder for public health efforts to reduce obesity rates, especially if GLP-1 drugs are used widely but not sustained long-term.
The 2025 expert advisory from major medical societies (including the American Society for Nutrition) emphasizes that without nutritional and behavioral support during and after GLP-1 treatment, weight regain is almost inevitable and can lead to muscle loss, nutrient deficiencies, and a return to emotional eating [5]. They recommend that clinicians screen for disordered eating and emotional triggers before starting these drugs and provide ongoing lifestyle counseling to prevent rebound. If that doesn't happen at scale, the population-level benefit of GLP-1s could be undermined by the rebound effect.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2025, 3 from 2024 or later, 3 in Q1 journals, collectively cited 266 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs
In a meta-analysis of 36 studies, semaglutide showed the highest weight regain after discontinuation (mean difference of 5.15 kg regained), followed by exenatide (3.06 kg), liraglutide (1.50 kg), and orlistat (1.66 kg), indicating that rebound is common and drug-dependent.
Weight stigma and health behaviors: evidence from the Eating in America Study
In a survey of 2,022 U.S. adults, weight stigma was significantly associated with greater disordered eating, comfort eating, sleep disturbance, and alcohol use, even after controlling for BMI, suggesting that stigma can worsen health behaviors during weight regain.
Night eating, weight, and health behaviors in adults participating in the Daily24 study
Among 1,017 adults, higher night eating severity was associated with higher BMI, greater consumption of sugar-sweetened beverages and fast food, and lower fruit/vegetable intake, linking night eating to obesity and poor diet.
Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
In a survey of 101 patients on GLP-1 agonists, participants reported significantly improved awareness of hunger cues and reduced eating in response to emotional, external, and situational cues while on the drug, but these benefits reversed after discontinuation.
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
An expert advisory from four major medical organizations highlights that GLP-1 therapy without nutritional and behavioral support leads to weight regain, muscle loss, and nutrient deficiencies, and recommends screening for disordered eating and emotional triggers before starting treatment.
Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study
In a retrospective cohort study, patients with binge eating disorder who received semaglutide alone showed greater reductions in binge eating scale scores compared to those on lisdexamfetamine or topiramate, suggesting semaglutide can treat binge eating, but this effect is lost when the drug is stopped.